Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160407 · ClinicalTrials.gov registry record · Phase 4
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 4 study, sponsored by St. Louis University.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT00160407 is a Phase 4 study that has completed, run by St. Louis University. The registered enrollment target is 50 participants.
The verdict
NCT00160407, a Phase 4 study, has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic changes that are typical of NASH.
Interventions
- DRUG Orlistat (Xenical)
- BEHAVIORAL 1400 kcal diet (30% fat)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160407
The ClinicalTrials.gov registry entry for NCT00160407 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Orlistat (Xenical) is the first listed.
NCT00160407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160407 about?
NCT00160407 is a clinical study titled "Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)". The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic changes that are typical of NASH.
What is the current status of trial NCT00160407?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2003-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00160407?
The interventions under investigation include: Orlistat (Xenical) (DRUG), 1400 kcal diet (30% fat) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00160407?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.